1. Home
  2. Labeler Index
  3. American Health Packaging
  4. 68084-782
  5. Product Images: Divalproex Sodium

Product Images Divalproex Sodium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Divalproex Sodium NDC 68084-782 by American Health Packaging, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

250 mg Blister

250 mg Blister

250 mg Carton

250 mg Carton

This is a medication called Divalproex Sodium, which comes in a delayed-release tablet form. It is prescribed through a medical professional and comes in a bottle containing 100 tablets. The medication guide should be included with each patient's prescription. The tablets contain Divalproex sodium equivalent to valproic acid, with a standard dosage specified in the package insert. It should be stored at a temperature between 20° to 25°C and kept away from children. The package should not be used if the blister is torn or broken. The drug product is manufactured and packaged by American Health Packaging in Columbus, Ohio.*

500 mg Blister

500 mg Blister

500 mg Carton

500 mg Carton

This is a medication package of Divalproex Sodium Delayed-Release Tablets, USP with Valproic Acid Activity. The tablets come in 500mg strength and there are 90 tablets in total (9 x 10) for prescription use only. Each enteric-coated tablet contains Divalproex sodium USP equivalent to valproic acid. The usual dosage should be seen in the package insert. It is important to keep the tablets out of reach of children and do not use if the blister pack is torn or broken. Store between 20 to 25°C (68 to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). The medication should be accompanied by a medication guide to be given to each patient. The package was distributed by American Health Packaging based in Columbus, Ohio.*

AHP77601

AHP77601

AHP78261

AHP78261

Figure 1

Figure 1

Figure 2

Figure 2

The text describes a figure, specifically Figure 2, showing the reduction in CPS rate. The figure displays two sets of data: one for Divaproex Sodium DefayedRelease Tablets and the other for Placsbo. The figure also includes a bar graph with levels ranging from 0 to 50 and a section indicating that 9% of patients improved, while some experienced no change, and some worsened.*

Figure 3

Figure 3

The text describes a figure or graph named "Reduction In CPS Rate" represented by Figure 3. The graph shows two categories or groups, "High Dose" and "Low Dose" with their respective percentage values. It also includes three sections "Improvement," "No Change," and "Worsening" that depict the percentage of patients who experienced these outcomes.*

Figure 4

Figure 4

This is a figure showing the mean 4-week migraine rates for two studies on the effects of placebo and divalproex sodium delayed-release tablets. The mean dose for divalproex sodium delayed-release tablets was 1,087 mg/day in Study 1 and the dose varied between 500 or 1,000 mg/day in Study 2.*

Structure

Structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.